Serina Therapeutics, Inc. Financing Cash Flow
Serina Therapeutics, Inc. (SER) reported Financing Cash Flow of $31.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $5.20M, a 6.61% decline year-over-year.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $26.06M, a 429.94% increase year-over-year.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $481.00K, a 90.44% decline year-over-year.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $6.44M, a 7393.02% increase year-over-year.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $17.41M, a 31.79% increase from fiscal 2024.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $13.21M, a 31.24% increase from fiscal 2023.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $10.07M, a 67.78% increase from fiscal 2022.
- Serina Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $6.00M, a 17.20% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $31.26M 10-Q · filed 2026-08-13 | $31.74M derived: sum of 3 quarters · filed 2026-08-13 | $38.18M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $26.06M 10-Q · filed 2026-05-14 | $26.54M derived: sum of 2 quarters · filed 2026-05-14 | $32.98M derived: sum of 3 quarters · filed 2026-05-14 | $38.55M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $481.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $6.92M derived: sum of 2 quarters · filed 2026-03-25 | $12.49M derived: sum of 3 quarters · filed 2026-08-13 | $17.41M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $6.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $12.01M derived: sum of 2 quarters · filed 2026-08-13 | $16.93M 10-Q · filed 2025-11-13 | $21.96M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $5.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $10.49M 10-Q · filed 2026-08-13 | $15.52M derived: sum of 3 quarters · filed 2026-08-13 | $15.60M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $4.92M 10-Q · filed 2026-05-14 | $9.95M derived: sum of 2 quarters · filed 2026-05-14 | $10.03M derived: sum of 3 quarters · filed 2026-05-14 | $15.40M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $5.12M derived: sum of 2 quarters · filed 2026-03-25 | $10.48M derived: sum of 3 quarters · filed 2026-03-25 | $13.21M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.45M derived: sum of 2 quarters · filed 2025-11-13 | $8.18M 10-Q · filed 2025-11-13 | $8.17M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $5.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $8.10M 10-Q · filed 2025-08-11 | $8.08M derived: sum of 3 quarters · filed 2025-08-11 | $8.08M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $2.73M 10-Q · filed 2025-05-08 | $2.71M derived: sum of 2 quarters · filed 2025-05-08 | $2.72M derived: sum of 3 quarters · filed 2025-05-08 | $2.71M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$11.00K derived: sum of 2 quarters · filed 2025-03-24 | -$22.00K derived: sum of 3 quarters · filed 2025-03-24 | $10.07M 10-K · filed 2025-03-24 | $17.50M 10-K · filed 2024-03-22 | |||
| 2023-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$9.00K derived: sum of 2 quarters · filed 2024-11-12 | $10.08M 10-Q · filed 2024-11-12 | $15.50M 10-Q · filed 2023-11-14 | $11.58M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $10.08M 10-Q · filed 2024-08-09 | $13.50M 10-Q · filed 2023-08-14 | $11.58M derived: sum of 3 quarters · filed 2024-08-09 | $12.58M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $10.09M 10-Q · filed 2024-05-14 | $11.50M 10-Q · filed 2023-05-12 | $11.59M derived: sum of 2 quarters · filed 2024-05-14 | $12.59M derived: sum of 3 quarters · filed 2024-05-14 | $14.59M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $2.50M derived: sum of 2 quarters · filed 2024-03-22 | $4.50M derived: sum of 3 quarters · filed 2024-03-22 | $6.00M 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.00M derived: sum of 2 quarters · filed 2023-11-14 | $4.50M 10-Q · filed 2023-11-14 | $6.00M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.50M 10-Q · filed 2023-08-14 | $5.00M derived: sum of 3 quarters · filed 2023-08-14 | $7.00M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $1.50M 10-Q · filed 2023-05-12 | $3.00M derived: sum of 2 quarters · filed 2023-05-12 | $5.00M derived: sum of 3 quarters · filed 2023-05-12 | $6.50M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.50M derived: sum of 2 quarters · filed 2023-03-31 | $5.00M derived: sum of 3 quarters · filed 2023-03-31 | $7.25M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.50M derived: sum of 2 quarters · filed 2022-11-10 | $5.75M 10-Q · filed 2022-11-10 | $6.00M 10-Q · filed 2021-11-12 | $6.74M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.75M 10-Q · filed 2022-08-12 | $4.00M 10-Q · filed 2021-08-13 | $4.74M derived: sum of 3 quarters · filed 2022-08-12 | $6.71M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-03-31 | $2.25M 10-Q · filed 2022-05-13 | $2.50M 10-Q · filed 2021-05-17 | $3.24M derived: sum of 2 quarters · filed 2022-05-13 | $5.21M derived: sum of 3 quarters · filed 2022-05-13 | $8.02M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $2.97M derived: sum of 2 quarters · filed 2022-03-29 | $5.78M derived: sum of 3 quarters · filed 2022-03-29 | $5.96M 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $4.78M derived: sum of 2 quarters · filed 2021-11-12 | $4.97M 10-Q · filed 2021-11-12 | $6.26M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $2.99M 10-Q · filed 2021-08-13 | $4.28M derived: sum of 3 quarters · filed 2021-08-13 | $4.77M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $185.00K 10-Q · filed 2021-05-17 | $1.47M derived: sum of 2 quarters · filed 2021-05-17 | $1.96M derived: sum of 3 quarters · filed 2021-05-17 | $1.95M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.77M derived: sum of 2 quarters · filed 2021-03-31 | $1.76M derived: sum of 3 quarters · filed 2021-03-31 | $6.26M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $487.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $478.00K derived: sum of 2 quarters · filed 2020-11-16 | $4.98M 10-Q · filed 2020-11-16 | $4.98M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $4.49M 10-Q · filed 2020-08-14 | $4.49M derived: sum of 3 quarters · filed 2020-08-14 | $4.75M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $4.50M 10-Q · filed 2020-05-14 | $4.50M derived: sum of 2 quarters · filed 2020-05-14 | $4.76M derived: sum of 3 quarters · filed 2020-05-14 | $9.76M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | $263.00K derived: sum of 2 quarters · filed 2020-03-31 | $5.26M derived: sum of 3 quarters · filed 2020-03-31 | $6.00M 10-K/A · filed 2020-03-31 | ||||
| 2018-09-30 | $263.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $5.26M derived: sum of 2 quarters · filed 2019-11-14 | $6.00M 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $5.74M 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $737.00K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $13.28M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |